The UK Life Sciences team advised SynAffix B.V. (“Synaffix”) and its selling shareholders on its sale to Lonza Group AG (“Lonza”). Under the terms of the sale and purchase agreement, Lonza have paid Synaffix’s shareholders an upfront payment of €100 million, with the potential for shareholders to receive an additional payment of up to €60 million contingent on financial performance.
Based in the Netherlands, Synaffix is a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs).
Lonza is a preferred global partner to the pharmaceutical, biotech and speciality ingredients markets. By combining technological insight with world-class manufacturing, scientific expertise and process excellence, Lonza helps its customers to deliver new and innovative medicines that help treat a wide range of diseases.
The Goodwin team, in London and Cambridge, was led by Andrew Harrow and Malcolm Bates and included Maria Dragun, Lucy Sharples, Talitha Shkopiak, Lucy Charlton, Georgia Powell, Heidi Fitchett and Matt Nestor.
For additional details, please read the press release.